The three-way study examined the safety and effectiveness of Novartis' Lucentis and Regeneron/Bayer's Eylea, both licensed to treat diabetic macular oedema (DME) and Roche/Genentech's Avastin ...

ranibizumab (Lucentis) +11]. "In this independent, government-sponsored diabetic macular oedema study, Eylea provided significantly greater efficacy, despite one fewer injection and fewer laser ...

Bayer said it needed expert input on high-dose Eylea to inform the launch, particularly at a time when the market was evolving quickly, as Lucentis biosimilars and Roche’s competing Vabysmo ...

Eylea, or aflibercept, had global sales of just under $10 billion in 2024, thanks to its strong competitive positioning and more attractive dosing regimen versus Lucentis and Avastin in ...